These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34796373)

  • 1. Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in France.
    Garin E; Pinaquy JB; Bailly C; Sengel C; Mariano-Goulart D; Edeline J; Blanc JF; Bouvier A; Tordo J; Rode A; Becker S; Sefrioui D; de Baere T; Somma C; Mastier C; Goupil J; Chevallier P; Regnault H; Vibert E; Manfredi S; Vicaut E; Patel B; Boucher E; Guiu B;
    Cardiovasc Intervent Radiol; 2022 Jan; 45(1):1-11. PubMed ID: 34796373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.
    Cheng B; Villalobos A; Sethi I; Wagstaff W; Galt J; Brandon D; Schuster DM; Bercu Z; Majdalany B; Kokabi N
    Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1194-1203. PubMed ID: 33890170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Nezami N; Kokabi N; Camacho JC; Schuster DM; Xing M; Kim HS
    Nucl Med Biol; 2018 Apr; 59():22-28. PubMed ID: 29448165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study.
    Kis B; Shridhar R; Mhaskar R; Gyano M; Frakes JM; El-Haddad G; Choi J; Kim RD; Hoffe SE
    J Vasc Interv Radiol; 2023 Sep; 34(9):1547-1555. PubMed ID: 37210030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter evaluation of the safety and efficacy of selective internal radiation therapy with yttrium-90 resin microspheres in Taiwan: data from the RESIN registry.
    Lee RC; Liang PC; Liang HL; Chen YF; Yu CY; Cheng PN; Hung CF; Hsia CY; Lai HC; Ho MC; Cheng YF; Liu YS; Chao Y; Chen CH
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1318-1327. PubMed ID: 38615197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres: long-term follow-up in a 134-patient cohort.
    Lewandowski RJ; Minocha J; Memon K; Riaz A; Gates VL; Ryu RK; Sato KT; Omary R; Salem R
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):486-93. PubMed ID: 24114004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.
    Garin E; Tselikas L; Guiu B; Chalaye J; Edeline J; de Baere T; Assenat E; Tacher V; Robert C; Terroir-Cassou-Mounat M; Mariano-Goulart D; Amaddeo G; Palard X; Hollebecque A; Kafrouni M; Regnault H; Boudjema K; Grimaldi S; Fourcade M; Kobeiter H; Vibert E; Le Sourd S; Piron L; Sommacale D; Laffont S; Campillo-Gimenez B; Rolland Y;
    Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):17-29. PubMed ID: 33166497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Segmental Yttrium-90 Radioembolization Using Glass Microspheres Greater than 400 Gray for the Treatment of Intrahepatic Cholangiocarcinoma: A Preliminary Experience.
    Yu Q; Patel M; Kwak D; Ungchusri E; Wang Y; Van Ha T; Zangan S; Marshall E; Little K; Baker T; Liao CY; Pillai A; Ahmed O
    J Vasc Interv Radiol; 2023 Nov; 34(11):1970-1976.e1. PubMed ID: 37532096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study.
    Rafi S; Piduru SM; El-Rayes B; Kauh JS; Kooby DA; Sarmiento JM; Kim HS
    Cardiovasc Intervent Radiol; 2013 Apr; 36(2):440-8. PubMed ID: 22956045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
    Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ;
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.
    Mouli S; Memon K; Baker T; Benson AB; Mulcahy MF; Gupta R; Ryu RK; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2013 Aug; 24(8):1227-34. PubMed ID: 23602420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.
    Weber M; Lam M; Chiesa C; Konijnenberg M; Cremonesi M; Flamen P; Gnesin S; Bodei L; Kracmerova T; Luster M; Garin E; Herrmann K
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1682-1699. PubMed ID: 35146577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review.
    Lee EW; Alanis L; Cho SK; Saab S
    Korean J Radiol; 2016; 17(4):472-88. PubMed ID: 27390539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma.
    Yu Q; Ungchusri E; Pillai A; Liao CY; Baker T; Fung J; DiSabato D; Zhang M; Liao C; Van Ha T; Ahmed O
    Eur Radiol; 2024 Apr; 34(4):2374-2383. PubMed ID: 37812295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation Segmentectomy for the Treatment of Primary Hepatic Malignancies of the Caudate Lobe: A Case Series.
    Arora M; Toskich BB; Lewis AR; Padula CA; Montazeri SA; Ritchie C; Frey G; Paz-Fumagalli R; McKinney JM; Devcic Z
    Cardiovasc Intervent Radiol; 2022 Oct; 45(10):1485-1493. PubMed ID: 36028573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Y90 Clinical Data Update: Cholangiocarcinoma, Neuroendocrine Tumor, Melanoma, and Breast Cancer Metastatic Disease.
    Padia SA
    Tech Vasc Interv Radiol; 2019 Jun; 22(2):81-86. PubMed ID: 31079715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.